Upregulation of KLF4 by methylseleninic acid in human esophageal squamous cell carcinoma cells: Modification of histone H3 acetylation through HAT/HDAC interplay

Molecular Carcinogenesis

Volumn 54, Issue 10, 2015, Pages 1051-1059

  Hu, Chenfei ^a   Liu, Mei ^a   Zhang, Wei ^a   Xu, Qing ^a   Ma, Kai ^a   Chen, Lechuang ^a   Wang, Zaozao ^a   He, Shun ^a   Zhu, Hongxia ^a   Xu, Ningzhi ^a  

^a CANCER HOSPITAL   (China)

Author keywords

GCN5; Histone acetylation; KLF4; Selenium

Indexed keywords

CASPASE 3; HISTONE ACETYLTRANSFERASE; HISTONE ACETYLTRANSFERASE GCN5; HISTONE DEACETYLASE; HISTONE H3; KRUPPEL LIKE FACTOR 4; MESSENGER RNA; METHYLSELENINIC ACID; SELENIC ACID; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; WATER; HISTONE; KRUPPEL LIKE FACTOR; METHYLSELENIC ACID; ORGANOSELENIUM DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL GROWTH; CHROMATIN IMMUNOPRECIPITATION; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FLOW CYTOMETRY; GENETIC TRANSFECTION; GROWTH INHIBITION; HISTONE ACETYLATION; HISTONE MODIFICATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA CELL; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING; ACETYLATION; ANIMAL; BAGG ALBINO MOUSE; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; DRUG EFFECTS; ESOPHAGEAL NEOPLASMS; METABOLISM; NUDE MOUSE; PROCEDURES; TUMOR CELL LINE;

ACETYLATION; ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; ESOPHAGEAL NEOPLASMS; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASES; HISTONES; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; ORGANOSELENIUM COMPOUNDS; PROMOTER REGIONS, GENETIC; UP-REGULATION;

EID: 84941616980     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22174     Document Type: Article

References (53)

1. Cai L, You NC, Lu H, et al. Dietary selenium intake, aldehyde dehydrogenase-2 and X-ray repair cross-complementing 1 genetic polymorphisms, and the risk of esophageal squamous cell carcinoma. Cancer 2006; 106:2345-2354.
2. Li H, Stampfer MJ, Giovannucci EL, et al. A prospective study of plasma selenium levels and prostate cancer risk. J Natl Cancer Inst 2004; 96:696-703.
3. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009; 301:39-51.
4. Mark SD, Qiao YL, Dawsey SM, et al. Prospective study of serum selenium levels and incident esophageal and gastric cancers. J Natl Cancer Inst 2000; 92:1753-1763.
5. Limburg PJ, Wei W, Ahnen DJ, et al. Randomized, placebo-controlled, esophageal squamous cell cancer chemoprevention trial of selenomethionine and celecoxib. Gastroenterology 2005; 129:863-873.
6. Sharma AK, Amin S. Post SELECT selenium on trial. Future Med Chem 2013; 5:163-174.
7. Li GX, Lee HJ, Wang Z, et al. Superior in vivo inhibitory efficacy of methylseleninic acid against human prostate cancer over selenomethionine or selenite. Carcinogenesis 2008; 29:1005-1012.
8. Ip C, Thompson HJ, Zhu Z, Ganther HE. In vitro and in vivo studies of methylseleninic acid: Evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Cancer Res 2000; 60:2882-2886.
9. Zhang W, Yan S, Liu M, et al. beta-Catenin/TCF pathway plays a vital role in selenium induced-growth inhibition and apoptosis in esophageal squamous cell carcinoma (ESCC) cells. Cancer Lett 2010; 296:113-122.
10. Wang L, Bonorden MJ, Li GX, et al. Methyl-selenium compounds inhibit prostate carcinogenesis in the transgenic adenocarcinoma of mouse prostate model with survival benefit. Cancer Prev Res (Phila) 2009; 2:484-495.
11. Wang Z, Hu H, Li G, et al. Methylseleninic acid inhibits microvascular endothelial G1 cell cycle progression and decreases tumor microvessel density. Int J Cancer 2008; 122:15-24.
12. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: Causes and therapies. Nat Rev Cancer 2001; 1:194-202.
13. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997; 389:349-352.
14. Mizzen C, Kuo MH, Smith E, et al. Signaling to chromatin through histone modifications: How clear is the signal? Cold Spring Harb Symp Quant Biol 1998; 63:469-481.
15. Peterson CL, Laniel MA. Histones and histone modifications. Curr Biol 2004; 14:R546-R551.
16. Ganesan A, Nolan L, Crabb SJ, Packham G. Epigenetic therapy: Histone acetylation, DNA methylation and anti-cancer drug discovery. Curr Cancer Drug Targets 2009; 9:963-981.
17. Xiang N, Zhao R, Song G, Zhong W. Selenite reactivates silenced genes by modifying DNA methylation and histones in prostate cancer cells. Carcinogenesis 2008; 29:2175-2181.
18. Kassam S, Goenaga-Infante H, Maharaj L, Hiley CT, Juliger S, Joel SP. Methylseleninic acid inhibits HDAC activity in diffuse large B-cell lymphoma cell lines. Cancer Chemther Pharmacol 2011; 68:815-821.
19. Zhou C, Liu S, Zhou X, et al. Overexpression of human pituitary tumor transforming gene (hPTTG), is regulated by beta-catenin/TCF pathway in human esophageal squamous cell carcinoma. Int J Cancer 2005; 113:891-898.
20. Zeng H, Wu M, Botnen JH. Methylselenol, a selenium metabolite, induces cell cycle arrest in G1 phase and apoptosis via the extracellular-regulated kinase 1/2 pathway and other cancer signaling genes. J Nutr 2009; 139:1613-1618.
21. Kuo MH, Brownell JE, Sobel RE, et al. Transcription-linked acetylation by Gcn5p of histones H3 and H4 at specific lysines. Nature 1996; 383:269-272.
22. Liu S, Zhang H, Zhu L, Zhao L, Dong Y. Kruppel-like factor 4 is a novel mediator of selenium in growth inhibition. Mol Cancer Res 2008; 6:306-313.
23. Kouzarides T. Chromatin modifications and their function. Cell 2007; 128:693-705.
24. Doyle K, Fitzpatrick FA. Redox signaling, alkylation (carbonylation) of conserved cysteines inactivates class I histone deacetylases 1, 2 and 3 and antagonizes their transcriptional repressor function. J Biol Chem 2010; 285:17417-17424.
25. Lee JI, Nian H, Cooper AJ, et al. Alpha-keto acid metabolites of naturally occurring organoselenium compounds as inhibitors of histone deacetylase in human prostate cancer cells. Cancer Prev Res (Phila) 2009; 2:683-693.
26. Nian H, Bisson WH, Dashwood WM, Pinto JT, Dashwood RH. Alpha-keto acid metabolites of organoselenium compounds inhibit histone deacetylase activity in human colon cancer cells. Carcinogenesis 2009; 30:1416-1423.
27. Rajendran P, Ho E, Williams DE, Dashwood RH. Dietary phytochemicals, HDAC inhibition, and DNA damage/repair defects in cancer cells. Clin Epigenetics 2011; 3:4.
28. Weekley CM, Harris HH. Which form is that? The importance of selenium speciation and metabolism in the prevention and treatment of disease. Chem Soc Rev 2013; 42:8870-8894.
29. Brownell JE, Zhou J, Ranalli T, et al. Tetrahymena histone acetyltransferase A: A homolog to yeast Gcn5p linking histone acetylation to gene activation. Cell 1996; 84:843-851.
30. Tjeertes JV, Miller KM, Jackson SP. Screen for DNA-damage-responsive histone modifications identifies H3K9Ac and H3K56Ac in human cells. EMBO J 2009; 28:1878-1889.
31. Jin Q, Yu LR, Wang L, et al. Distinct roles of GCN5/PCAF-mediated H3K9ac and CBP/p300-mediated H3K18/27ac in nuclear receptor transactivation. EMBO J 2011; 30:249-262.
32. Horwitz GA, Zhang K, McBrian MA, Grunstein M, Kurdistani SK, Berk AJ. Adenovirus small e1a alters global patterns of histone modification. Science 2008; 321:1084-1085.
33. Liu Y, Xing ZB, Zhang JH, Fang Y. Akt kinase targets the association of CBP with histone H3 to regulate the acetylation of lysine K18. FEBS Lett 2013; 587:847-853.
34. Sakamoto S, Wakae K, Anzai Y, et al. E2A and CBP/p300 act in synergy to promote chromatin accessibility of the immunoglobulin kappa locus. J Immunol 2012; 188:5547-5560.
35. Chen ZY, Rex S, Tseng CC. Kruppel-like factor 4 is transactivated by butyrate in colon cancer cells. J Nutr 2004; 134:792-798.
36. Kee HJ, Kook H. Kruppel-like factor 4 mediates histone deacetylase inhibitor-induced prevention of cardiac hypertrophy. J Mol Cell Cardiol 2009; 47:770-780.
37. Davie JR. Inhibition of histone deacetylase activity by butyrate. J Nutr 2003; 133:2485S-2493S.
38. Kee HJ, Kwon JS, Shin S, Ahn Y, Jeong MH, Kook H. Trichostatin A prevents neointimal hyperplasia via activation of Kruppel like factor 4. Vascul Pharmacol 2011; 55:127-134.
39. Wang Z, Zang C, Rosenfeld JA, et al. Combinatorial patterns of histone acetylations and methylations in the human genome. Nat Genet 2008; 40:897-903.
40. Shahbazian MD, Grunstein M. Functions of site-specific histone acetylation and deacetylation. Annu Rev Biochem 2007; 76:75-100.
41. Li R, Liang J, Ni S, et al. A mesenchymal-to-epithelial transition initiates and is required for the nuclear reprogramming of mouse fibroblasts. Cell Stem Cell 2010; 7:51-63.
42. Samavarchi-Tehrani P, Golipour A, David L, et al. Functional genomics reveals a BMP-driven mesenchymal-to-epithelial transition in the initiation of somatic cell reprogramming. Cell Stem Cell 2010; 7:64-77.
43. Rowland BD, Bernards R, Peeper DS. The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. Nat Cell Biol 2005; 7:1074-1082.
44. Yu F, Li J, Chen H, et al. Kruppel-like factor 4 (KLF4) is required for maintenance of breast cancer stem cells and for cell migration and invasion. Oncogene 2011; 30:2161-2172.
45. Akaogi K, Nakajima Y, Ito I, et al. KLF4 suppresses estrogen-dependent breast cancer growth by inhibiting the transcriptional activity of ERalpha. Oncogene 2009; 28:2894-2902.
46. Shie JL, Chen ZY, O'Brien MJ, Pestell RG, Lee ME, Tseng CC. Role of gut-enriched Kruppel-like factor in colonic cell growth and differentiation. Am J Physiol Gastrointest Liver Physiol 2000; 279:G806-G814.
47. Wei D, Gong W, Kanai M, et al. Drastic down-regulation of Kruppel-like factor 4 expression is critical in human gastric cancer development and progression. Cancer Res 2005; 65:2746-2754.
48. Dang DT, Chen X, Feng J, Torbenson M, Dang LH, Yang VW. Overexpression of Kruppel-like factor 4 in the human colon cancer cell line RKO leads to reduced tumorigenecity. Oncogene 2003; 22:3424-3430.
49. Wang J, Place RF, Huang V, et al. Prognostic value and function of KLF4 in prostate cancer: RNAa and vector-mediated overexpression identify KLF4 as an inhibitor of tumor cell growth and migration. Cancer Res 2010; 70:10182-10191.
50. Yori JL, Seachrist DD, Johnson E, et al. Kruppel-like factor 4 inhibits tumorigenic progression and metastasis in a mouse model of breast cancer. Neoplasia 2011; 13:601-610.
51. Li Q, Jia Z, Wang L, et al. Disruption of Klf4 in villin-positive gastric progenitor cells promotes formation and progression of tumors of the antrum in mice. Gastroenterology 2012; 142:531-542.
52. Hu W, Hofstetter WL, Li H, et al. Putative tumor-suppressive function of Kruppel-like factor 4 in primary lung carcinoma. Clin Cancer Res 2009; 15:5688-5695.
53. Yasunaga J, Taniguchi Y, Nosaka K, et al. Identification of aberrantly methylated genes in association with adult T-cell leukemia. Cancer Res 2004; 64:6002-6009.